Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

GlucoTrack: Company Addresses the Diabetes Testing and Monitoring Conundrum

GlucoTrack ( NDAQ:GCTK ) is an American medical device company focused on design, development and commercialization. The company is developing proprietary painless and non-invasive blood glucose monitoring devices for both Type 2 diabetes and prediabetes, a market almost ...
Simon Druker | January 16, 2023 |

Why Provention Bio Is in My Portfolio

Quite often when I write about companies I'm just about the only one doing so. It's in these situations that Tailwinds can add value by not only highlighting our investment thesis, but in educating investors about a company for which there is little to no publicly avail...
Streetwise Reports | August 26, 2019 |

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. Yesterday afternoon, The Woodlands, Tex.-based Lexicon Pharmaceu...
Streetwise Reports | September 12, 2019 |

vTv Therapeutics' Shares open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

Shares of vTv Therapeutics traded 50% higher after the company reported positive results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 used in the treatment of patients with type 1 diabetes. Clinical-stage pharmaceutical company focused on treating ...
Streetwise Reports | February 11, 2020 |

DIAGNOS poised for parabolic move as first of new cardio AI Applications comes to market

DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company that pioneered ' C omputer A ssisted R etinal A nalysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients a...
James O'Rourke | May 5, 2020 |

Buzz on the Bullboards: 2021 The Year of the Cannabis Comeback?

(TAAT CEO, Setti Coscarella. Image via TAAT Lifestyle & Wellness Ltd.) If you look at one set of market headlines around COVID-19, you would read about stimulus packages, vaccine rollouts, and a general lightening in sentiment … but if you look news outlets, you see...
Stockhouse Editorial | February 10, 2021 |

Nemaura Medical Accelerates Launch of sugarBEAT Wearable Continuous Glucose Monitor

Shares of Nemaura Medical traded 20% higher after the firm reported that it is investigating using its non-invasive continuous glucose monitor sugarBEAT® jointly with its planned health subscription service BEAT®diabetes, to provide personalized lifestyle c...
Streetwise Reports | February 27, 2020 |

Buzz on the Bullboards: When Stocks Go Up … Must They Come Down?

(Challenger 350 promotional image via Bombardier Inc.) Many markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with some companies having a rougher start to 2021 than others. If a stock goes u...
Stockhouse Editorial | January 27, 2021 |

Tandem Increases Unit Sales of t:slim X2 Insulin Pumps 290% Worldwide

Tandem Diabetes Care's second quarter earnings highlighted a 290% increase in unit sales of its t:slim X2 insulin pumps that feature integrated continuous glucose monitoring and remote software update capability. Insulin delivery and diabetes medical device mak...
Streetwise Reports | August 6, 2019 |

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. Clinical-stage biotechnology company Allogene Therapeutics Inc. (ALLO:NAS...
Streetwise Reports | May 15, 2020 |
1 2 3 4 5 6 7 8 9 10 ...